The GLP-1 Pathway Stack

GLP-1 receptor agonism is the most clinically validated mechanism in metabolic research right now. This stack pairs the established injectable peptide with Orforglipron — the small molecule oral GLP-1 receptor agonist that removes the injection requirement entirely. Same target. Different chemistry. Different practical profile.

Why these two compounds

GLP-1 (Glucagon-Like Peptide-1) is the endogenous incretin hormone that slows gastric emptying, suppresses appetite via the gut-brain axis, and drives glucose-dependent insulin secretion. The injectable GLP-1 receptor agonist class (semaglutide, tirzepatide) is the fastest-growing drug class in pharmaceutical history, with weight loss efficacy and cardiovascular outcomes data that has reshaped metabolic medicine. The injectable form has well-characterised pharmacokinetics, established dosing protocols, and the most extensive clinical dataset of any compound in this catalog.

Orforglipron is a non-peptide small molecule GLP-1 receptor agonist developed by Eli Lilly and currently in Phase 3 trials. Its mechanism at the receptor is equivalent to injectable GLP-1 agonists, but its delivery is entirely oral — no injection, no refrigeration, no reconstitution. Phase 2 data showed dose-dependent weight loss of 9–14% over 36 weeks, alongside favorable glucose lowering comparable to approved GLP-1 injectables. Being a small molecule rather than a peptide, it has a different stability profile and absorption mechanism (absorbed in the small intestine rather than injected subcutaneously).

This pairing is of interest to researchers studying receptor saturation vs. oral bioavailability trade-offs, comparative pharmacodynamics between peptide and small-molecule GLP-1 agonism, and the practical differences between delivery routes at the same receptor target.

Protocol reference

These compounds address the same receptor and should not be run simultaneously in a clinical context without specific research rationale. This stack is appropriate for sequential comparison protocols or split-cohort research designs where the primary variable is delivery chemistry, not receptor target. Consult current Phase 3 trial protocols for Orforglipron dosing reference.

What’s included

• GLP-1 — HPLC-verified ≥99% purity
• Orforglipron — HPLC-verified ≥99% purity

For research use only. Not for human consumption. Not medical advice. COA available on every batch. HPLC-verified ≥99% purity on all compounds.